Na Julaị 27, 2023, Lilly kwupụtara na mmụta Mount-3 nke Tirzepatide maka ọgwụgwọ ndị ọrịa buru ibu yana ọmụmụ Mount-4 maka idobe oke ibu nke ndị ọrịa buru ibu eruola isi njedebe na isi njedebe nke abụọ.Nke a bụ nyocha nke atọ na nke anọ na-aga nke ọma nke atọ nke Tirzepatide nwetara mgbe Ugwu-1 na Ugwu-2 gasịrị.
SURMOUNT-3 (NCT04657016) bụ multicenter, randomized, abụọ-kpuru, yiri, placebo na-achịkwa ikpe na-edebanye aha ngụkọta nke 806 sonyere emebere iji gosipụta ịdị elu Tirzepatide karịa placebo n'ihe banyere mgbanwe pasentị na mgbanwe ịdị arọ mgbe randomization na pasentị. ndị sonyere bụ ndị tụfuru ≥5% mgbe randomization na 72 izu.
Nsonaazụ ọmụmụ SURMOUNT-3 gosiri na Tirzepatide zutere njedebe niile, ya bụ na mgbe izu 72 nke ọgwụgwọ ọgwụ, ndị ọrịa nọ n'òtù Tirzepatide nwetara pasentị dị elu nke oke ibu site na ntọala ma e jiri ya tụnyere placebo, yana ọnụ ọgụgụ dị elu nke ndị ọrịa nọ na otu Tirzepatide. nwetara pasentị dị arọ karịa 5%.Data ụlọ ọgwụ akọwapụtara akọwapụtara na ndị ọrịa na-agwọ Tirzepatide tụfuru nkezi 21.1% nke ịdị arọ ahụ ma e jiri ya tụnyere placebo;Ejikọtara ya na oge ntinye aka nke izu iri na abụọ, ndị ọrịa a na-agwọ na Tirzepatide tụfuru nkezi nke 26.6 pasent nke ịdị arọ ahụ ha.Na mgbakwunye, 94.4% nke ndị ọrịa tụfuru ≥5% nke ibu ha na otu Tirzepatide, ma e jiri ya tụnyere 10.7% na otu placebo.
SURMOUNT-4 (NCT04660643) bụ multicenter, randomized, abụọ-kpuru, yiri, placebo-achịkwa ikpe na-edebanye aha ngụkọta nke 783 sonyere e mere iji gosi na Tirzepatide dị elu na placebo na pasent arọ mgbanwe na 88-izu randomization.
Nsonaazụ gosiri na mgbe izu abụọ-ìsì nke 37 ~ 88 izu, ndị ọrịa nọ na Tirzepatide otu tụfuru ibu karịa na placebo otu.N'ihe gbasara nchekwa, ọbụghị ọmụmụ SURMOUNT-3 ma ọ bụ SURMOUNT-4 ahụghị akara nchekwa ọhụrụ.
Kemgbe mmalite nke Novo Nordisk's blockbuster diet ọgwụ Semaglutide, yana nkwado siri ike nke Musk, ọ ghọwo ngwaahịa ama ama na ịntanetị na-atụ egwu na eze ọnwụ dị ugbu a.Achọ ahịa ịbelata ibu dị ukwuu, yana enwere naanị ọgwụ abụọ GLP-1 na-ebelata ibu ugbu a n'ahịa, Liraglutide na Semaglutide, mana Liraglutide bụ nkwadebe na-eme mkpụmkpụ, nke enweghị ike ịsọ mpi na nkwadebe ogologo oge n'ihe gbasara nnabata onye ọrịa. , na ụwa mbelata ibu dị ugbu a bụ nke Semaglutide nwa oge.
Ọzọkwa eze nke GLP-1 ubi, Lilly agụụ na-acha anụnụ anụnụ oké osimiri nke arọ ọnwụ ahịa - otú Lilly malitere a ịma aka na mbụ nzọ na Tirzepatide iji weghara ebe ke ibu ibu ahịa.
Tirzepatide bụ GIPR/GLP-1R dual agonist kwa izu, GIP (glucose na-adabere insulin na-akpali polypeptide) bụ onye ọzọ so na ezinụlọ glucagon peptide, na-enwe mmetụta nke ịkwalite mmepụta insulin n'ụzọ dabere na insulin na-akpali akpali secretion glucagon na hypoglycemic. steeti, GIPR/GLP-1R dual agonist nwere ike imepụta njikwa shuga ọbara, oke ibu na mmetụta ndị ọzọ site na ịkpali ma GIP na GLP-1 ụzọ mgbada.FDA kwadoro Tirzepatide na 2022-5 (aha ahia: Mounjaro) maka iji ya na nri na mmega ahụ iji melite njikwa glycemic na ndị okenye nwere ụdị ọrịa shuga 2.
Oge nzipu: Sep-18-2023